(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual revenue growth rate of 50.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.13%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.77%.
X4 Pharmaceuticals's revenue in 2025 is $31,364,000.On average, 5 Wall Street analysts forecast XFOR's revenue for 2025 to be $177,469,535, with the lowest XFOR revenue forecast at $56,729,123, and the highest XFOR revenue forecast at $213,081,532. On average, 5 Wall Street analysts forecast XFOR's revenue for 2026 to be $149,093,397, with the lowest XFOR revenue forecast at $95,165,998, and the highest XFOR revenue forecast at $197,973,061.
In 2027, XFOR is forecast to generate $736,303,493 in revenue, with the lowest revenue forecast at $206,482,430 and the highest revenue forecast at $1,833,276,856.